Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor

This publication has 53 references indexed in Scilit:

• Systemic delivery of micelles loading with paclitaxel using N-succinyl-palmitoyl-chitosan decorated with cRGDyK peptide to inhibit non-small-cell lung cancer
  International Journal of Pharmaceutics, 2015
• BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence
  Nature Genetics, 2014
• High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer
  Annals of Oncology, 2014
• EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promote s NSCLC cell proliferation and metastasis by affecting the epithelial–mesenchymal transition
  Cell Death & Disease, 2014
• EZH2 Silencing with RNA Interference Induces G₂/M Arrest in Human Lung Cancer CellsIn Vitro
  BioMed Research International, 2014
• Cancer treatment and survivorship statistics, 2012
  CA: A Cancer Journal for Clinicians, 2012
• Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
  Cancer Treatment Reviews, 2012
• Cancer statistics, 2012
  CA: A Cancer Journal for Clinicians, 2012
• Genetic and epigenetic changes in lung carcinoma and their clinical implications
  Laboratory Investigation, 2011
• Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance
  Cancer, 2010